

#	Article	IF	CITATIONS
1	Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. British Journal of Cancer, 2000, 82, 1427-1432.	6.4	252
2	The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. British Journal of Cancer, 2000, 83, 63-68.	6.4	136
3	Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer, 2001, 34, S83-S89.	2.0	25
4	VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. Journal of Pathology, 2001, 193, 325-332.	4.5	55
5	Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. British Journal of Cancer, 2002, 87, 1437-1444.	6.4	52
6	Association of hypoxiaâ€inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer, 2002, 95, 1055-1063.	4.1	207
7	Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. Journal of Pathology, 2002, 197, 677-683.	4.5	97
8	Platelet endothelial cell adhesion molecule-1 and angiogenic factor expression in idiopathic membranous nephropathy. American Journal of Kidney Diseases, 2003, 41, 360-365.	1.9	13
9	Evaluation of Angiogenesis in Canine Seminomas by Quantitative Immunohistochemistry. Journal of Comparative Pathology, 2003, 128, 252-259.	0.4	55
10	The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology, 2003, 43, 33-39.	2.9	62
11	The angiogenic switch for vascular endothelial growth factor (VEGF)â€A, VEGFâ€B, VEGFâ€C, and VEGFâ€D in the adenoma–carcinoma sequence during colorectal cancer progression. Journal of Pathology, 2003, 200, 183-194.	4.5	191
12	Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma. British Journal of Cancer, 2003, 88, 553-559.	6.4	35
13	Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. European Journal of Surgical Oncology, 2003, 29, 879-883.	1.0	41
14	Endogenous myocardial angiogenesis and revascularization using a gastric submucosal patch. Annals of Thoracic Surgery, 2003, 75, 1443-1449.	1.3	23
15	The Role of Growth Factors for Disease and Therapy in Diseases of the Head and Neck. DNA and Cell Biology, 2003, 22, 593-606.	1.9	8
16	Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification. Clinical Cancer Research, 2004, 10, 7965-7971.	7.0	215
17	Angiogenesis and Lymphangiogenesis in Parathyroid Proliferative Lesions. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2890-2896.	3.6	30
18	CITED4 Inhibits Hypoxia-Activated Transcription in Cancer Cells, and Its Cytoplasmic Location in Breast Cancer Is Associated with Elevated Expression of Tumor Cell Hypoxia-Inducible Factor $11\pm$. Cancer Research, 2004, 64, 6075-6081.	0.9	60

#	ARTICLE	IF	Citations
19	Vascular endothelial growth factor (VEGF)â€A and plateletâ€derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. Journal of Pathology, 2004, 203, 721-728.	4.5	149
20	Bone Marrow Microvessel Density (MVD) in Adult Acute Myeloid Leukemia (AML): Therapy Induced Changes and Effects on Survival. Leukemia and Lymphoma, 2004, 45, 1185-1190.	1.3	69
21	Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. British Journal of Cancer, 2005, 92, 94-101.	6.4	232
22	Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. Journal of Clinical Pathology, 2005, 58, 1033-1038.	2.0	50
23	The Androgen Receptor Is Significantly Associated with Vascular Endothelial Growth Factor and Hypoxia Sensing via Hypoxia-Inducible Factors HIF-1a, HIF-2a, and the Prolyl Hydroxylases in Human Prostate Cancer. Clinical Cancer Research, 2005, 11, 7658-7663.	7.0	144
24	C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1α gene define HIF-1α protein expression in non-small cell lung cancer. Lung Cancer, 2006, 53, 257-262.	2.0	35
25	Protein microarrays: A new tool for profiling antibody cross-reactivity. Human Antibodies, 2006, 14, 7-15.	1.5	29
26	Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?. Breast Cancer Research and Treatment, 2006, 100, 1-11.	2.5	112
27	Hypoxia inducible factors $1\hat{l}_{\pm}$ and $2\hat{l}_{\pm}$ are associated with VEGF expression and angiogenesis in gallbladder carcinomas. Journal of Surgical Oncology, 2006, 94, 242-247.	1.7	40
28	Angiogenesis in nodal B cell lymphomas: a high throughput study. Journal of Clinical Pathology, 2006, 60, 476-482.	2.0	56
29	Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients. Journal of Clinical Oncology, 2006, 24, 3623-3628.	1.6	178
30	Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway—A Report of the Tumour Angiogenesis Research Group. Journal of Clinical Oncology, 2006, 24, 4301-4308.	1.6	183
31	The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. European Journal of Endocrinology, 2006, 155, 849-857.	3.7	87
32	Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocrine-Related Cancer, 2006, 13, 931-944.	3.1	76
33	Role of lymphangiogenesis in epithelial ovarian cancer. British Journal of Cancer, 2006, 94, 1650-1657.	6.4	27
34	Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma. British Journal of Cancer, 2007, 97, 223-230.	6.4	119
35	Prevention of Irradiation-induced Salivary Hypofunction by Microvessel Protection in Mouse Salivary Glands. Molecular Therapy, 2007, 15, 2101-2106.	8.2	95
36	Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis. BJU International, 2007, 86, 80-86.	2.5	37

3

#	Article	IF	CITATIONS
37	Expression of theforkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia. Prostate, 2007, 67, 1091-1098.	2.3	40
38	The effect of old age on liver oxygenation and the hepatic expression of VEGF and VEGFR2. Experimental Gerontology, 2007, 42, 1012-1019.	2.8	20
39	Expression of Vascular Endothelial Growth Factor and its Receptors in Canine Lymphoma. Journal of Comparative Pathology, 2007, 137, 30-40.	0.4	28
40	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncology, The, 2008, 9, 342-351.	10.7	257
41	Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leukemia and Lymphoma, 2008, 49, 2181-2186.	1.3	18
42	Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. British Journal of Cancer, 2009, 101, 1749-1757.	6.4	98
43	Induction of the vascular endothelial growth factor pathway in the brain of adults with fatal falciparum malaria is a nonâ€specific response to severe disease. Histopathology, 2010, 57, 282-294.	2.9	17
44	Anti-human Vascular Endothelial Growth Factor (VEGF) Antibody Selection for Immunohistochemical Staining of Proliferating Blood Vessels. Journal of Histochemistry and Cytochemistry, 2010, 58, 109-118.	2.5	22
45	Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1236-1243.	0.8	7
46	Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. British Journal of Cancer, 2011, 104, 1877-1881.	6.4	53
47	Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs. Research in Veterinary Science, 2012, 92, 444-450.	1.9	12
48	Estudo clÃnico, histopatológico e imunoistoquÃmico de neoplasias mamárias em cadelas. Arquivo Brasileiro De Medicina Veterinaria E Zootecnia, 2012, 64, 1094-1100.	0.4	10
49	Conventional and Doppler ultrasound for the differentiation of benign and malignant canine mammary tumours. Journal of Small Animal Practice, 2012, 53, 332-337.	1.2	35
50	Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival. Clinical and Experimental Metastasis, 2012, 29, 11-17.	3.3	14
51	Role of bone marrow-derived stem cells, renal progenitor cells and stem cell factor in chronic renal allograft nephropathy. Alexandria Journal of Medicine, 2013, 49, 235-247.	0.6	0
52	Overexpression of LC3A autophagy protein in follicular and diffuse large B-cell lymphomas. Hematology/ Oncology and Stem Cell Therapy, 2013, 6, 20-25.	0.9	13
53	Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leukemia and Lymphoma, 2014, 55, 558-564.	1.3	20
54	CD105 expression in oral capillary hemangiomas and cavernous hemangiomas. Journal of Oral Science, 2015, 57, 45-53.	1.7	8

#	Article	IF	CITATIONS
55	Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas. Oncology Letters, 2016, 11, 399-404.	1.8	15
56	Elevated <scp>VEGFA</scp> mRNA levels in oral squamous cell carcinomas and tumor margins: a preliminary study. Journal of Oral Pathology and Medicine, 2016, 45, 481-485.	2.7	21
57	Clinical Significance of VEGF-A and Microvessel Density in Diffuse Large B-Cell Lymphoma and Low-Grade Follicular Lymphoma. Acta Clinica Croatica, 2017, 56, 588-593.	0.2	6
58	Physical activity differentially regulates VEGF, PIGF, and their receptors in the human placenta. Physiological Reports, 2021, 9, e14710.	1.7	19
59	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2000, 8, 104-109.	2.0	15
60	Immunohistochemical Measurement of Tumor Vascular Endothelial Growth Factor in Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2000, 8, 104-109.	1.2	18
61	Therapeutic suppression of translation initiation factor elF4E expression reduces tumor growth without toxicity. Journal of Clinical Investigation, 2007, 117, 2638-2648.	8.2	330
62	Association of VEGF with Regional Lymph Node Metastasis in Breast IDC. Journal of Medical Sciences (Faisalabad, Pakistan), 2011, 12, 18-23.	0.0	1
63	Vascular Endothelial Growth Factor Expression in the Pathological Angiogenesis in Oral Squamous Cell Carcinoma., 0,,.		2
64	Appearance and evolution of the endothelial cell. , 2022, , 1-13.		O
65	Expression of Vascular Endothelial Growth Factor in Uveal Melanoma Is Independent of 6p21-Region Copy Number. Clinical Cancer Research, 2005, 11, 73-78.	7.0	22